DSP-7888

DRUG3 trials

Sponsors

Sumitomo Pharma Co., Ltd., Osaka University

Conditions

Acute Myeloid Leukemia in RemissionDiffuse Intrinsic Pontine GliomaGlioblastomaMyelodysplastic Syndrome

Phase 1

Study of DSP-7888 in Patients With Myelodysplastic Syndrome

CompletedNCT02436252

Sumitomo Pharma Co., Ltd.Myelodysplastic Syndrome

Start: 2015-05-31End: 2020-03-31Updated: 2022-04-12

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

CompletedNCT02750891

Sumitomo Pharma Co., Ltd.Diffuse Intrinsic Pontine Glioma, Glioblastoma

Start: 2016-04-30End: 2020-01-31Updated: 2022-04-12

Phase 2

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine Dainippon Sumitomo Phama(DSP)-7888 for Acute Myeloid Leukemia Patients.

Osaka UniversityAcute Myeloid Leukemia in Remission

Start: 2020-06-12End: 2024-04-30Target: 100Updated: 2021-03-03

Related Papers

PS1344 PHASE 1/2 STUDY OF DSP‐7888 IN PATIENTS WITH HIGHER‐RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AFTER FAILURE OF AZACITIDINE (AZA) THERAPY

HemaSphere2019-06-01